Related Experiment Video

Updated: Jun 10, 2026

Sampling Cerebrospinal Fluid and Blood from Lateral Tail Vein in Rats During EEG Recordings
10:46

Sampling Cerebrospinal Fluid and Blood from Lateral Tail Vein in Rats During EEG Recordings

Published on: September 1, 2023

Effects of AEDs on biomarkers in people with epilepsy: CRP, HbA1c and eGFR

Alan W C Yuen1, Gail S Bell, Janet L Peacock

  • 1Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, London, United Kingdom. alan@yuen.co.uk

Epilepsy Research
|August 17, 2010
PubMed

Insights

Certain antiepileptic drugs (AEDs) may impact health markers associated with mortality risk in epilepsy patients. Valproate and phenytoin showed potential benefits, while lamotrigine indicated a possible negative effect on kidney function.

Area of Science:

  • Neurology
  • Clinical Pharmacology
  • Biomarkers

Background:

  • People with epilepsy face a 2-3 times higher mortality ratio than the general population.
  • Biomarkers like C-reactive protein (CRP), glycosylated hemoglobin (HbA1c), and estimated glomerular filtration rate (eGFR) are linked to premature death risk.

Purpose of the Study:

  • To investigate the potential impact of antiepileptic drug (AED) use on specific mortality-associated biomarkers in individuals with refractory epilepsy.
  • To assess whether common AEDs influence CRP, HbA1c, and eGFR levels.

Main Methods:

  • A cohort of 125 patients with refractory epilepsy was analyzed.
  • Multiple regression analysis was employed to examine the association between AED use (valproate, phenytoin, lamotrigine) and biomarker levels (CRP, HbA1c, eGFR).

Main Results:

  • Valproate use was linked to significantly lower CRP levels and higher eGFR.
  • Phenytoin use was associated with a modest reduction in HbA1c.
  • Lamotrigine use showed a correlation with decreased eGFR, suggesting a potential negative impact on kidney function.

Conclusions:

  • Preliminary findings suggest that certain AEDs may differentially affect health markers associated with mortality.
  • Valproate and phenytoin may offer beneficial effects on these markers, whereas lamotrigine might have detrimental effects on renal function.
  • Further controlled studies, particularly in patients on monotherapy, are essential to confirm these observations.

More Related Videos

Event Related Potentials (ERPs) and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder (ADHD)10:02

Event Related Potentials (ERPs) and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder (ADHD)

Published on: March 12, 2020

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...